Table 5
Follow up results
| hEGF (100 μg/ml) | Placebo | hEGF (30 μg/ml) | Placebo | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | C | VA | No | C | VA | No | C | VA | No | C | VA | ||||
| 6 Months | 9 | a | 0.4 | 9 | b | 0.6 | 9 | a | 0.7 | 9 | a,c | 0.7 | |||
| 1 Year | 8 | 0 | 0.5 | 8 | 0 | 0.7 | 9 | a | 0.7 | 7 | c | 0.7 | |||
| 2 Years | 7 | d | 0.7 | 8 | 0 | 0.8 | 9 | 0 | 0.7 | 7 | 0 | 0.7 | |||
-
No = number of patients. C = complications: a, suture problem; b, endothelial rejection; c, stromal rejection → repeat penetrating keratoplasty; d, endothelial rejection → repeat penetrating keratoplasty; 0, no complications. VA = best corrected mean visual acuity (Snellen fraction).
